Laboratorios Farmaceuticos Rovi, S.A. (FRA:41L)

Market Cap	4.04B +49.9%
Revenue (ttm)	743.48M -2.7%
Net Income	140.44M +2.6%
EPS	2.75 +2.7%
Shares Out	n/a
PE Ratio	28.74
Forward PE	25.72
Dividend	0.76 (0.97%)
Ex-Dividend Date	Jul 14, 2025

Volume	60
Average Volume	31
Open	79.45
Previous Close	78.50
Day's Range	78.35 - 79.45
52-Week Range	46.30 - 84.35
Beta	n/a
RSI	49.92
Earnings Date	May 6, 2026

About FRA:41L

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 2,045
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41L

Financial Performance

In 2025, FRA:41L's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.